Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
63 participants
OBSERVATIONAL
2014-09-02
2024-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
NCT05529992
Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India
NCT04429984
Home Therapy With VPRIV in Gaucher's Disease
NCT01356537
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease
NCT04721366
A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
NCT04094181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gaucher Disease Participants Treated With VPRIV
Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who are either naïve to treatment or participants that have been treated with another therapeutic agent for Gaucher disease
* Participants who start VPRIV treatment or transition from VPRIV clinical studies during the enrollment period
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Konan
Kōnan, Aichi-ken, Japan
Nagoya
Nagoya, Aichi-ken, Japan
Kitakyushu
Kitakyushu, Fukuoka, Japan
Kurume
Kurume, Fukuoka, Japan
Fukuyama
Fukuyama, Hiroshima, Japan
Higashihiroshima
Higashihiroshima, Hiroshima, Japan
Obihiro
Obihiro, Hokkaido, Japan
Sagamihara
Sagamihara, Kanagawa, Japan
Sendai
Sendai, Miyagi, Japan
Suita
Suita, Osaka, Japan
Tondabayashi
Tondabayashi, Osaka, Japan
Kawagoe
Kawagoe, Saitama, Japan
Tokorozawa
Tokorozawa, Saitama, Japan
Moriyama
Moriyama, Shiga, Japan
Otsu
Ōtsu, Shiga, Japan
Matsue
Matsue, Shimane, Japan
Hamamatsu
Hamamatsu, Shizuoka, Japan
Hamamatsu
Hamamatsu, Shizuoka, Japan
Iwata
Iwata, Shizuoka, Japan
Minato
Minato, Tokyo, Japan
Sumida-ku
Sumida-ku, Tokyo, Japan
Yonago
Yonago, Tottori, Japan
Chiba
Chiba, , Japan
Gifu
Gifu, , Japan
Hiroshima
Hiroshima, , Japan
Hiroshima
Hiroshima, , Japan
Kagoshima
Kagoshima, , Japan
Kumamoto
Kumamoto, , Japan
Kyoto
Kyoto, , Japan
Okayama
Okayama, , Japan
Osaka
Osaka, , Japan
Osaka
Osaka, , Japan
Osaka
Osaka, , Japan
Saitama
Saitama, , Japan
Shizuoka
Shizuoka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sagara R, Ishigaki M, Otsuka M, Murayama K, Ida H, Fernandez J. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan. Orphanet J Rare Dis. 2021 Dec 4;16(1):502. doi: 10.1186/s13023-021-02119-2.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHP-GCB-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.